Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lacrystat
- Development stage
- Phase 2
- Lead developer
- Viatris
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Lacrystat is a commercially available artificial tear eye drop formulation used for ocular lubrication. It is primarily indicated for the relief of dry eye symptoms and ocular irritation. In a clinical setting, Lacrystat has been studied as a prophylactic treatment to prevent dacryostenosis (lacrimal duct obstruction) in patients undergoing chemotherapy with docetaxel, which is known to be secreted in tears and cause inflammation of the tear ducts. The product functions by mechanically washing away dacryotoxic agents and maintaining the hydration of the ocular surface. It is manufactured by Meda Pharma, a subsidiary of Viatris.
- Brand names
- Lacrystat
- Other names
- artificial tears
Beyond the preview
Go deeper on Lacrystat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lacrystat.